Compare GE Aerospace (GE) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance

GE Aerospace (GE) trades at $305.62, up 0.66% on the day, but faces a near-term bearish technical signal despite strong fundamentals. The company reported robust earnings beats in recent quarters, with Q2 2026 EPS of $2.02 exceeding the $1.86 estimate. Revenue growth is accelerating, reaching $45.86 billion in 2025, while net income margins improved to 17.72%. However, the stock's high valuation multiples, including a P/E of 36.04, and a significant $12 billion acquisition of Consolidated Precision Products, present both opportunity and scrutiny.

The outlook remains positive driven by strong defense demand and shareholder returns, including a $20 billion buyback and raised dividend. Analyst consensus is strongly bullish with a $409.60 price target, though risks include integration challenges from the CPP deal, cost pressures, and high debt levels. The stock's current price is approximately 25% below the consensus target, suggesting potential upside if execution risks are managed.

Zimmer Biomet (ZBH) trades at $88.91, up 0.47% on the day, with a bearish technical signal but strong recent earnings beats. The company reported Q2 2026 EPS of $2.07, exceeding expectations, and maintains a solid gross profit margin of 69.87%. Revenue growth is steady, reaching $8.23B in 2025, though net income margin has moderated. Analyst consensus is a 'Buy' with a $103.11 price target, indicating potential upside from current levels.

The outlook for ZBH is cautiously optimistic, supported by earnings momentum and a diversified medical technology portfolio. Key risks include rising debt levels, with debt-to-asset ratio increasing to 32.57% in 2025, and competitive pressures in the healthcare sector. Institutional ownership trends show continued interest, but investors should monitor margin sustainability and capital expenditure efficiency.